Abstract
Uveitis is a diverse group of potentially sight-threatening intraocular inflammatory diseases of infectious or autoimmune etiology and accounts for more than 10% of severe visual handicaps in the United States. Pathology derives from the presence of inflammatory cells in the optical axis and sustained production of cytotoxic cytokines and other immuneregulatory proteins in the eye. The main therapeutic goals are to down-regulate the immune response, preserve the integrity of the ocular architecture and eventually eliminate the inciting uveitogenic stimuli. Current therapy is based on topical or systemic corticosteroid with or without second line agents and serious adverse effects of these drugs are the impetus for development of less toxic and more specific therapies for uveitis. This review summarizes the pathophysiology of uveitis, molecular mechanisms that regulate the initiation and progression of uveitis and concludes with emerging strategies for the treatment of this group of potentially blinding diseases.
Keywords: B cell therapy, IL-12 cytokines, IL-35-expressing Breg cell (i35-Breg), interleukin 35 (IL-35), regulatory B cells (Breg), therapeutic cytokines, uveitis.
Current Molecular Medicine
Title:Ocular Inflammatory Diseases: Molecular Pathogenesis and Immunotherapy
Volume: 15 Issue: 6
Author(s): C.E. Egwuagu, L. Sun, S.-H. Kim and I.M. Dambuza
Affiliation:
Keywords: B cell therapy, IL-12 cytokines, IL-35-expressing Breg cell (i35-Breg), interleukin 35 (IL-35), regulatory B cells (Breg), therapeutic cytokines, uveitis.
Abstract: Uveitis is a diverse group of potentially sight-threatening intraocular inflammatory diseases of infectious or autoimmune etiology and accounts for more than 10% of severe visual handicaps in the United States. Pathology derives from the presence of inflammatory cells in the optical axis and sustained production of cytotoxic cytokines and other immuneregulatory proteins in the eye. The main therapeutic goals are to down-regulate the immune response, preserve the integrity of the ocular architecture and eventually eliminate the inciting uveitogenic stimuli. Current therapy is based on topical or systemic corticosteroid with or without second line agents and serious adverse effects of these drugs are the impetus for development of less toxic and more specific therapies for uveitis. This review summarizes the pathophysiology of uveitis, molecular mechanisms that regulate the initiation and progression of uveitis and concludes with emerging strategies for the treatment of this group of potentially blinding diseases.
Export Options
About this article
Cite this article as:
Egwuagu C.E., Sun L., Kim S.-H. and Dambuza I.M., Ocular Inflammatory Diseases: Molecular Pathogenesis and Immunotherapy, Current Molecular Medicine 2015; 15 (6) . https://dx.doi.org/10.2174/1566524015666150731095426
DOI https://dx.doi.org/10.2174/1566524015666150731095426 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nephroangiosclerosis and Its Pharmacological Approach
Current Vascular Pharmacology Hypertension in Hemodialysis Patients
Current Hypertension Reviews Current Options for the Pharmacotherapy of Obesity
Current Pharmaceutical Design The Phage Display Technique: Advantages and Recent Patents
Recent Patents on DNA & Gene Sequences Clinical and Forensic Signs Related to Cocaine Abuse
Current Drug Abuse Reviews Adverse Effects and Drug Interactions of Biologic Agents
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Efalizumab
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Current Indications for Infective Endocarditis Antibiotic Prophylaxis
Infectious Disorders - Drug Targets Role of Alpha-1 Antitrypsin (AAT) in Ocular Allergy and Uveitis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Old Versus New Anticoagulants: Focus on Pharmacology
Recent Patents on Cardiovascular Drug Discovery Antiepileptic Drug-Induced Hypersensitivity Syndrome Reactions
Current Drug Safety Cow’s Milk Allergy: Where have we Come from and where are we Going?
Endocrine, Metabolic & Immune Disorders - Drug Targets The Small Bowel: An Imaging Guide
Current Medical Imaging The Indian Pediatric HIV Epidemic: A Systematic Review
Current HIV Research Engineered Protein Protease Inhibitors
Current Enzyme Inhibition Occupational Respiratory Pathology in Russia: Current Trends and Challenges
Current Respiratory Medicine Reviews Cutaneous Adverse Drug Reactions Caused by Antituberculosis Drugs
Inflammation & Allergy - Drug Targets (Discontinued) Occupational Allergy in Healthcare Workers
Recent Patents on Inflammation & Allergy Drug Discovery Genetic Predictors of Drug Hypersensitivity
Current Pharmaceutical Design Drug Induced Cutaneous Manifestations due to Treatment of Gastrointestinal Disorders
Current Drug Metabolism